(ACLS) Axcelis Technologies - Ratings and Ratios
Ion Implanters, Spare Parts, Upgrades, Maintenance, Training
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 48.1% |
| Value at Risk 5%th | 74.6% |
| Relative Tail Risk | -5.78% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.52 |
| Alpha | -2.03 |
| CAGR/Max DD | 0.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.614 |
| Beta | 1.587 |
| Beta Downside | 1.582 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.84% |
| Mean DD | 39.75% |
| Median DD | 44.18% |
Description: ACLS Axcelis Technologies November 10, 2025
Axcelis Technologies (NASDAQ: ACLS) designs, manufactures, and services ion-implantation and related semiconductor processing equipment for chip makers across the U.S., Europe, and Asia-Pacific. Its product line spans high-energy/high-current implanters for advanced nodes, medium-current tools for legacy processes, and a suite of aftermarket services such as used-tool refurbishment, spare-part logistics, upgrades, and customer training, all sold through a direct sales organization.
Key performance indicators that investors watch include: (1) Revenue growth – the company reported FY 2024 revenue of $1.02 billion, a 7 % YoY increase driven by higher equipment orders and service contracts; (2) Order backlog – a roughly $1.3 billion backlog representing ~12 months of forward-filled demand, indicating a relatively tight supply-demand balance; and (3) Gross margin – stable around 38 % despite inflationary pressure on components, reflecting pricing power in a niche, high-mix market.
Sector-level drivers shaping Axcelis’ outlook are the global semiconductor capital-expenditure cycle (with 2024-25 fab-spending projected to rise 9 % YoY by SEMI), the shift toward advanced-node technologies that increase demand for high-energy implanters, and geopolitical incentives (e.g., U.S. CHIPS Act funding) that are accelerating domestic fab expansion, thereby boosting domestic equipment spend.
For a deeper, data-rich analysis of ACLS’s valuation dynamics and comparable peers, you may find ValueRay’s research platform a useful next step.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (135.9m TTM) > 0 and > 6% of Revenue (6% = 51.2m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA -3.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 92.02% (prev 80.86%; Δ 11.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 137.7m > Net Income 135.9m (YES >=105%, WARN >=100%) |
| Net Debt (-114.8m) to EBITDA (178.5m) ratio: -0.64 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (31.4m) change vs 12m ago -3.75% (target <= -2.0% for YES) |
| Gross Margin 44.68% (prev 44.28%; Δ 0.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 63.43% (prev 80.39%; Δ -16.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.75 (EBITDA TTM 178.5m / Interest Expense TTM 10.9m) >= 6 (WARN >= 3) |
Altman Z'' 7.33
| (A) 0.58 = (Total Current Assets 984.0m - Total Current Liabilities 199.0m) / Total Assets 1.35b |
| (B) 0.36 = Retained Earnings (Balance) 488.8m / Total Assets 1.35b |
| (C) 0.12 = EBIT TTM 161.0m / Avg Total Assets 1.35b |
| (D) 1.47 = Book Value of Equity 487.2m / Total Liabilities 331.8m |
| Total Rating: 7.33 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.12
| 1. Piotroski 5.50pt |
| 2. FCF Yield 6.08% |
| 3. FCF Margin 14.54% |
| 4. Debt/Equity 0.07 |
| 5. Debt/Ebitda -0.64 |
| 6. ROIC - WACC (= 1.85)% |
| 7. RoE 13.31% |
| 8. Rev. Trend -5.38% |
| 9. EPS Trend -1.56% |
What is the price of ACLS shares?
Over the past week, the price has changed by +9.73%, over one month by +7.54%, over three months by +12.67% and over the past year by +23.55%.
Is ACLS a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACLS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96.8 | 6.6% |
| Analysts Target Price | 96.8 | 6.6% |
| ValueRay Target Price | 94.9 | 4.5% |
ACLS Fundamental Data Overview November 25, 2025
P/E Trailing = 18.1321
P/E Forward = 17.9211
P/S = 2.8313
P/B = 2.3365
P/EG = 1.23
Beta = 1.726
Revenue TTM = 853.1m USD
EBIT TTM = 161.0m USD
EBITDA TTM = 178.5m USD
Long Term Debt = 42.3m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 6.27m USD (from shortTermDebt, last quarter)
Debt = 72.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -114.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.04b USD (2.42b + Debt 72.7m - CCE 449.6m)
Interest Coverage Ratio = 14.75 (Ebit TTM 161.0m / Interest Expense TTM 10.9m)
FCF Yield = 6.08% (FCF TTM 124.0m / Enterprise Value 2.04b)
FCF Margin = 14.54% (FCF TTM 124.0m / Revenue TTM 853.1m)
Net Margin = 15.93% (Net Income TTM 135.9m / Revenue TTM 853.1m)
Gross Margin = 44.68% ((Revenue TTM 853.1m - Cost of Revenue TTM 472.0m) / Revenue TTM)
Gross Margin QoQ = 41.57% (prev 44.90%)
Tobins Q-Ratio = 1.51 (Enterprise Value 2.04b / Total Assets 1.35b)
Interest Expense / Debt = 9.29% (Interest Expense 6.75m / Debt 72.7m)
Taxrate = 13.81% (4.16m / 30.1m)
NOPAT = 138.8m (EBIT 161.0m * (1 - 13.81%))
Current Ratio = 4.95 (Total Current Assets 984.0m / Total Current Liabilities 199.0m)
Debt / Equity = 0.07 (Debt 72.7m / totalStockholderEquity, last quarter 1.02b)
Debt / EBITDA = -0.64 (Net Debt -114.8m / EBITDA 178.5m)
Debt / FCF = -0.93 (Net Debt -114.8m / FCF TTM 124.0m)
Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.05% (Net Income 135.9m / Total Assets 1.35b)
RoE = 13.31% (Net Income TTM 135.9m / Total Stockholder Equity 1.02b)
RoCE = 15.15% (EBIT 161.0m / Capital Employed (Equity 1.02b + L.T.Debt 42.3m))
RoIC = 13.60% (NOPAT 138.8m / Invested Capital 1.02b)
WACC = 11.75% (E(2.42b)/V(2.49b) * Re(11.86%) + D(72.7m)/V(2.49b) * Rd(9.29%) * (1-Tc(0.14)))
Discount Rate = 11.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.42%
[DCF Debug] Terminal Value 63.15% ; FCFE base≈144.8m ; Y1≈129.1m ; Y5≈108.9m
Fair Price DCF = 36.93 (DCF Value 1.14b / Shares Outstanding 31.0m; 5y FCF grow -13.36% → 3.0% )
EPS Correlation: -1.56 | EPS CAGR: 3.85% | SUE: 1.12 | # QB: 4
Revenue Correlation: -5.38 | Revenue CAGR: 1.01% | SUE: 3.87 | # QB: 4
EPS next Quarter (2026-03-31): EPS=1.04 | Chg30d=+0.072 | Revisions Net=+3 | Analysts=6
EPS next Year (2026-12-31): EPS=4.56 | Chg30d=+0.337 | Revisions Net=+6 | Growth EPS=+2.4% | Growth Revenue=+7.1%
Additional Sources for ACLS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle